SELENOP and breast cancer: Interestingly, in in-silico survival analysis, we found a correlation of higher Bcl-3 expression and lower KLHL4 and SEPP1 expression with unfavorable outcome of endocrinally treated breast cancer patients that suffered from a ERα+/PR+-tumor suggesting that not only Bcl-3 is linked to endocrine resistance, but also its target genes KLHL4 and SEPP1.